Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Docetaxel and epirubicin salvage regimen in relapsed anthracycline-sensitive metastatic breast cancer patients after anthracycline-containing adjuvant therapy

Full metadata record
DC Field Value Language
dc.contributor.authorSeo, Jae Hong-
dc.contributor.authorSung, Hwa Jung-
dc.contributor.authorPark, Kyong Hwa-
dc.contributor.authorChoi, In Keun-
dc.contributor.authorOh, Sang Cheul-
dc.contributor.authorShin, Sang Won-
dc.contributor.authorKim, Yeul Hong-
dc.contributor.authorKim, Jun Suk-
dc.contributor.authorKim, Ae-Ree-
dc.contributor.authorLee, Jae-Bok-
dc.contributor.authorKoo, Bum Hwan-
dc.date.accessioned2021-09-08T20:25:40Z-
dc.date.available2021-09-08T20:25:40Z-
dc.date.issued2009-02-
dc.identifier.issn0167-6997-
dc.identifier.issn1573-0646-
dc.identifier.urihttps://scholar.korea.ac.kr/handle/2021.sw.korea/120704-
dc.description.abstractOur aim in this paper is to verify the efficacy and safety of a epirubicin and docetaxel salvage regimen for anthracycline sensitive metastatic breast cancer patients who have relapsed after anthracycline-containing adjuvant therapy. Thirty-two metastatic breast cancer patients were treated with epirubicin and docetaxel every 21 days. Of the 31 evaluable patients, there were 13/31 (41.9%) partial responses and no complete responses. Median time to progression was 12 months (95% CI, 4-60 months) and median survival duration was 41 months (95% CI, 1.2-80.8 months). According to the Cox model, ECOG performance and response group were statistically significant variables, and visceral metastasis was a borderline significant variable with regards to overall survival. Although this salvage regimen showed a high rate of hematologic toxicities, it was a relatively active regimen with manageable toxicities and no cardiac dysfunction. We propose that this salvage regimen could be carefully used in anthracycline sensitive metastatic breast cancer patients who have relapsed after anthracycline-containing adjuvant therapy.-
dc.format.extent7-
dc.language영어-
dc.language.isoENG-
dc.publisherSPRINGER-
dc.titleDocetaxel and epirubicin salvage regimen in relapsed anthracycline-sensitive metastatic breast cancer patients after anthracycline-containing adjuvant therapy-
dc.typeArticle-
dc.publisher.location네덜란드-
dc.identifier.doi10.1007/s10637-008-9151-2-
dc.identifier.scopusid2-s2.0-62749130644-
dc.identifier.wosid000261957000008-
dc.identifier.bibliographicCitationINVESTIGATIONAL NEW DRUGS, v.27, no.1, pp 67 - 73-
dc.citation.titleINVESTIGATIONAL NEW DRUGS-
dc.citation.volume27-
dc.citation.number1-
dc.citation.startPage67-
dc.citation.endPage73-
dc.type.docTypeArticle-
dc.description.isOpenAccessN-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.relation.journalResearchAreaOncology-
dc.relation.journalResearchAreaPharmacology & Pharmacy-
dc.relation.journalWebOfScienceCategoryOncology-
dc.relation.journalWebOfScienceCategoryPharmacology & Pharmacy-
dc.subject.keywordPlus1ST-LINE CHEMOTHERAPY-
dc.subject.keywordPlusPLUS DOCETAXEL-
dc.subject.keywordPlusSTANDARD-
dc.subject.keywordPlusMBC-
dc.subject.keywordAuthorEpirubicin-
dc.subject.keywordAuthorDocetaxel-
dc.subject.keywordAuthorAnthracycline-
dc.subject.keywordAuthorSensitive-
dc.subject.keywordAuthorMetastatic breast cancer-
Files in This Item
There are no files associated with this item.
Appears in
Collections
Graduate School > Department of Biomedical Sciences > 1. Journal Articles
College of Medicine > Department of Medical Science > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Oh, Sang Cheul photo

Oh, Sang Cheul
Graduate School (Department of Biomedical Sciences)
Read more

Altmetrics

Total Views & Downloads

BROWSE